Evidence map›Paper›PMID 30929571›Full record

ArticleCirculation research2019

Impaired Retinal Vessel Dilation Predicts Mortality in End-Stage Renal Disease.

Roman Günthner, Henner Hanssen, Christine Hauser, Susanne Angermann, Georg Lorenz, Stephan Kemmner, Julia Matschkal, Matthias C Braunisch, Claudius Kuechle, Lutz Renders and 12 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01152892 (Risk Stratification in End Stage Renal Disease), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01152892 unknown statusnot on this map

Risk Stratification in End Stage Renal Disease (ISAR)

TypeobservationalSponsorTechnical University of MunichRan2010 to 2020Enrolled500ConditionsEnd Stage Renal Disease, Chronic Kidney Disease, Cardiovascular Event, Sudden Cardiac Death
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. BOLD MRI to Evaluate the Effects of Sacubitril/Valsartan on Renal Protection in Type 2 Diabetics.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Cognitive impairment and microvascular function in end-stage renal disease.International journal of methods in psychiatric research · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 3 countries.

Roman GünthnerNephrology, Technical University of Munich.
Henner HanssenSport, Exercise and Health, University of Basel.
Christine HauserNephrology, Technical University of Munich.
Susanne AngermannNephrology, Technical University of Munich.
Georg LorenzNephrology, Technical University of Munich.
Stephan KemmnerNephrology, Technical University of Munich.
Julia MatschkalNephrology, Technical University of Munich.
Matthias C BraunischNephrology, Technical University of Munich.
Claudius KuechleNephrology, Technical University of Munich.
Lutz RendersNephrology, Technical University of Munich.
Philipp MoogNephrology, Technical University of Munich.
Siegfried WassertheurerHealth and Environment, AIT Austrian Institute of Technology GmbH.
Marcus BaumannNephrology, Technical University of Munich.
Hans-Peter HammesMedical Faculty Mannheim, Heidelberg University.
Christopher C MayerCenter for Health and Bioresources, Biomedical Systems, AIT Austrian Institute of Technology GmbH, AUSTRIA.
Bernhard HallerInstitute for Medical Statistics and Epidemiology, Technical University of Munich.
Sarah StryeckGottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz.
Tobias MadlGottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz.
Javier Carbajo-LozoyaNephrology, Technical University of Munich.
Uwe HeemannNephrology, Technical University of Munich.
Konstantin KotliarMedical Engineering and Technomathematics, FH Aachen University of Applied Sciences.
Christoph SchmadererNephrology, Technical University of Munich.
Klinikum rechts der Isar · DETechnical University of Munich · DEAustrian Institute of Technology · ATBioTechMed-Graz · ATMedical University of Graz · ATUniversity Medical Centre Mannheim · DEUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationalePatients with end-stage renal disease (ESRD) are characterized by increased cardiovascular (CV) and all-cause mortality due to advanced remodeling of the macro- and microvascular beds.

objectiveThe aim of this study was to determine whether retinal microvascular function can predict all-cause and CV mortality in patients with ESRD. METHODS AND

resultsIn the multicenter prospective observational ISAR (Risk Stratification in End-Stage Renal Disease) study, data on dynamic retinal vessel analysis (DVA) was available in a sub-cohort of 214 dialysis patients (mean age 62.6{plus minus}15.0; 32% female). Microvascular dysfunction was quantified by measuring maximum arteriolar (aMax) and venular dilation (vMax) of retinal vessels in response to flicker light stimulation. During a mean follow-up of 44 months, 55 patients died, including 25 CV and 30 non-CV fatal events. vMax emerged as a strong independent predictor for all-cause mortality. In the Kaplan-Meier analysis, individuals within the lowest tertile of vMax showed significantly shorter three-year survival rates than those within the highest tertile (66.9{plus minus}5.8% vs 92.4{plus minus}3.3%). Uni- and multivariate hazard ratios for all-cause mortality per SD increase of vMax were 0.62 [0.47;0.82] and 0.65[0.47;0.91], respectively. aMax and vMax were able to significantly predict nonfatal and fatal CV events (HR 0.74[0.57;0.97] and 0.78[0.61;0.99], respectively).

conclusionsOur results provide the first evidence that impaired retinal venular dilation is a strong and independent predictor of all-cause mortality in hemodialyzed ESRD patients. DVA provides added value for prediction of all-cause mortality and may be a novel diagnostic tool to optimize CV risk stratification in ESRD and other high-risk CV cohorts. CLINICAL

trial registrationNCT01152892.

Indexed as

renal failureretinal vesselsvascular biomarker

Identifiers

PMID30929571
OpenAlexW2927432035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.